-
公开(公告)号：EP4159238A1
公开(公告)日：2023-04-05
申请号：EP21817364.9
申请日：2021-06-01
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Tianjin Medical University Cancer Institute and Hospital
发明人： ZHANG, Xiquan , WANG, Xunqiang , YU, Ding , LIU, Tao , ZHAN, Xiaole , WU, Naiying
IPC分类号： A61K39/395 , C07D215/22 , C07K16/28 , A61P35/00
摘要： Provided are a combined pharmaceutical composition of an anti-PD-L1 antibody and a c-Met kinase inhibitor, specifically, a combined pharmaceutical composition of an anti-PD-L1 antibody and N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-f luorophenyl)cyclopropane-1,1-dicarboxamide, and the use of the combined pharmaceutical composition in the treatment of cancers, in particular, gastric cancer or liver cancer.
-
公开(公告)号：EP4302763A1
公开(公告)日：2024-01-10
申请号：EP22762608.2
申请日：2022-03-03
发明人： FENG, Fan , YU, Ding , WANG, Xunqiang , ZHANG, Xiquan , BAI, Yanfeng , YANG, Chaoqiang , ZHANG, Yuying
IPC分类号： A61K31/565 , C07D403/14 , A61P35/00
摘要： The present disclosure relates to a combined pharmaceutical composition containing a CDK4/6 inhibitor and a use thereof, and specifically relates to a combined pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and fulvestrant. The present disclosure further relates to a use of the combined pharmaceutical composition in treating breast cancer. The combined pharmaceutical composition of the present disclosure produces better therapeutic effects in reducing tumor growth or even eliminating tumors.
-
公开(公告)号：EP4410836A1
公开(公告)日：2024-08-07
申请号：EP22875057.6
申请日：2022-09-29
申请人： Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group , CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
发明人： YANG, Anqi , ZHANG, Xiquan , YU, Ding , LV, Peng , WANG, Xunqiang , TIAN, Xin , CHEN, Qin
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： A61K39/395 , C07K16/28 , A61P35/00
摘要： An anti-CD47 antibody for combined treatment of a blood tumor. Provided are the use of the anti-CD47 antibody and a second therapeutic agent in the preparation of a drug for treating a blood tumor in a subject. Provided is a method for treating a blood tumor in a subject, comprising administering a therapeutically effective amount of the anti-CD47 antibody and the second therapeutic agent to a subject. Also provided are a pharmaceutical combination comprising the anti-CD47 antibody and the second therapeutic agent, and a kit.
-
公开(公告)号：EP3153169B1
公开(公告)日：2020-08-05
申请号：EP15803424.9
申请日：2015-06-05
发明人： WANG, Shanchun , WANG, Xunqiang , GU, Hongmei , DONG, Ping , XU, Hongjiang
IPC分类号： A61K31/4709 , A61K9/20 , A61K9/48 , A61P35/00
-
公开(公告)号：EP3231797B1
公开(公告)日：2020-02-26
申请号：EP15867543.9
申请日：2015-12-09
发明人： WANG, Xunqiang , MIAO, Yadong , ZHOU, Min , WANG, Shanchun , YANG, Ling , SHI, Wei
IPC分类号： C07D401/12 , A61K31/4709 , A61P35/00
-
6.发明公开
公开(公告)号：EP4361152A1
公开(公告)日：2024-05-01
申请号：EP22827576.4
申请日：2022-06-21
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Shouyao Holdings (Beijing) Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： TU, Lifan , ZHANG, Xiquan , WANG, Xunqiang , YU, Ding , HUANG, Jianqiang
IPC分类号： C07D487/04 , A61K31/519 , A61P37/06
CPC分类号： C07D487/04 , A61K31/519 , A61P37/06
摘要： The present invention relates to the use of a pyrrolopyrimidine compound and a pharmaceutical composition thereof for treating chronic graft versus host disease, and particularly relates to the use of a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof for treating chronic graft versus host disease.
-
公开(公告)号：EP4119562A1
公开(公告)日：2023-01-18
申请号：EP21767840.8
申请日：2021-03-09
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Shouyao Holdings (Beijing) Co., Ltd.
发明人： LIANG, Hongming , ZHANG, Xiquan , WANG, Xunqiang , YU, Ding , WANG, Dong , GE, Qi , WANG, Zhao , WANG, Yini
IPC分类号： C07D487/04 , A61K31/519 , A61P7/00
摘要： The present invention relates to use of a pyrrolopyrimidine compound for treating hemophagocytic syndrome, and particularly relates to use of a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof for treating hemophagocytic syndrome.
-
8.发明公开
公开(公告)号：EP3957631A1
公开(公告)日：2022-02-23
申请号：EP20790646.2
申请日：2020-04-20
发明人： ZHAN, Xiaole , TU, Lifan , YANG, Chaoqiang , ZHANG, Xiquan , WANG, Xunqiang , XU, Jie , XU,Ping , WANG,Chengqian
IPC分类号： C07D401/12 , A61K31/4709 , A61K45/06 , A61P35/00
摘要： The present invention belongs to the field of medicine, and provides a quinoline compound or a pharmaceutically acceptable salt thereof for treating Ewing's sarcoma, and particularly relates to use of compound I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating Ewing's sarcoma and use of compound I or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent in the preparation of a combination medicament for treating Ewing's sarcoma. The chemical name of compound I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine.
-
公开(公告)号：EP3939610A1
公开(公告)日：2022-01-19
申请号：EP20774316.2
申请日：2020-03-13
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Nanjing Shunxin Pharmaceutical Co., Ltd. of Chiatai Tianqing Pharmaceutical Group
发明人： WANG, Shanchun , WANG, Xunqiang , YU, Ding , LIU, Wenwen , SHU, Chao , FAN, Mengxue
IPC分类号： A61K39/395 , A61K31/4709 , A61P35/00
摘要： The present invention relates to the field of biomedicine and relates to a combined pharmaceutical composition used for treating small cell lung cancer, the composition comprising an anti-PD-L1 antibody and anlotinib, and having good anti-small cell lung cancer activity.
-
公开(公告)号：EP3854396A1
公开(公告)日：2021-07-28
申请号：EP19861634.4
申请日：2019-09-18
发明人： WANG, Shanchun , YU, Ding , WANG, Xunqiang , PENG, Bangan , LIU, Lu , DAI, Jie , ZHOU, Hang , MIAO, Yadong
IPC分类号： A61K31/4709 , A61P35/00
摘要： The present application relates to the field of medicine, and provided thereby is a quinoline derivative used for treating small cell lung cancer. The 1-[[[4-(4-fluoro-2-methyl-1 H -indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy] methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof as provided by the present application may be used for the treatment of small cell lung cancer, especially for patients suffering from refractory relapsed small cell lung cancer, which may significantly prolong the survival time thereof; in addition, the therapeutic effect on brain metastatic small cell lung cancer is also very significant.
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.021 秒)
